Literature DB >> 14655957

Early detection of ototoxicity using 1/6th-octave steps.

Stephen A Fausti1, Wendy J Helt, David S Phillips, Jane S Gordon, Gene W Bratt, Karen M Sugiura, Douglas Noffsinger.   

Abstract

The National Center for Rehabilitative Auditory Research has developed a protocol to provide early identification of ototoxicity for patients receiving ototoxic medications. The initial work involved patients with relatively good high-frequency hearing and resulted in the use of an individualized, sensitive frequency range separated by 1/6th-octave intervals. This protocol tested pure-tone frequencies at 1/6th-octave steps above 9 kHz, but only conventional audiometric frequencies were tested below 9 kHz. More recently, the testing protocol was expanded to include 1/6th-octave testing below 9 kHz. The primary question of interest was to determine whether adding 1/6th-octave test frequencies below 9 kHz would increase the ototoxicity detection rate for patients with poorer hearing. Results indicated 76 of the 210 (36.2%) ears that demonstrated initial ototoxic hearing change would have been missed or detected later if only conventional frequency testing was conducted.Therefore, for individuals with poorer hearing, expanding the use of the 1/6th-octave test protocol provides earlier identification of ototoxicity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14655957

Source DB:  PubMed          Journal:  J Am Acad Audiol        ISSN: 1050-0545            Impact factor:   1.664


  15 in total

1.  Distortion-product otoacoustic emission test performance for ototoxicity monitoring.

Authors:  Kelly M Reavis; Garnett McMillan; Donald Austin; Frederick Gallun; Stephen A Fausti; Jane S Gordon; Wendy J Helt; Dawn Konrad-Martin
Journal:  Ear Hear       Date:  2011-02       Impact factor: 3.570

2.  Multivariate DPOAE metrics for identifying changes in hearing: perspectives from ototoxicity monitoring.

Authors:  Dawn Konrad-Martin; Kelly M Reavis; Garnett P McMillan; Marilyn F Dille
Journal:  Int J Audiol       Date:  2012-02       Impact factor: 2.117

3.  Evaluation of audiometric threshold shift criteria for ototoxicity monitoring.

Authors:  Dawn Konrad-Martin; Kenneth E James; Jane S Gordon; Kelly M Reavis; David S Phillips; Gene W Bratt; Stephen A Fausti
Journal:  J Am Acad Audiol       Date:  2010-05       Impact factor: 1.664

4.  Tinnitus onset rates from chemotherapeutic agents and ototoxic antibiotics: results of a large prospective study.

Authors:  Marilyn F Dille; Dawn Konrad-Martin; Frederick Gallun; Wendy J Helt; Jane S Gordon; Kelly M Reavis; Gene W Bratt; Stephen A Fausti
Journal:  J Am Acad Audiol       Date:  2010-06       Impact factor: 1.664

5.  Pharmacokinetic modelling to predict risk of ototoxicity with intravenous tobramycin treatment in cystic fibrosis.

Authors:  Min Dong; Anna V Rodriguez; Chelsea A Blankenship; Gary McPhail; Alexander A Vinks; Lisa L Hunter
Journal:  J Antimicrob Chemother       Date:  2021-10-11       Impact factor: 5.790

6.  Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA).

Authors:  Dawn Konrad-Martin; Kelly M Reavis; Garnett McMillan; Wendy J Helt; Marilyn Dille
Journal:  J Rehabil Res Dev       Date:  2014

7.  High-frequency click-evoked otoacoustic emissions and behavioral thresholds in humans.

Authors:  Shawn S Goodman; Denis F Fitzpatrick; John C Ellison; Walt Jesteadt; Douglas H Keefe
Journal:  J Acoust Soc Am       Date:  2009-02       Impact factor: 1.840

8.  A Store-and-Forward Tele-Audiology Solution to Promote Efficient Screenings for Ototoxicity during Cisplatin Cancer Treatment.

Authors:  Marilyn F Dille; Garnett P McMillan; Wendy J Helt; Dawn Konrad-Martin; Peter Jacobs
Journal:  J Am Acad Audiol       Date:  2015-10       Impact factor: 1.664

Review 9.  Applying U.S. national guidelines for ototoxicity monitoring in adult patients: perspectives on patient populations, service gaps, barriers and solutions.

Authors:  Dawn Konrad-Martin; Gayla L Poling; Angela C Garinis; Candice E Ortiz; Jennifer Hopper; Keri O'Connell Bennett; Marilyn F Dille
Journal:  Int J Audiol       Date:  2017-11-20       Impact factor: 2.117

10.  Functional Impacts of Aminoglycoside Treatment on Speech Perception and Extended High-Frequency Hearing Loss in a Pediatric Cystic Fibrosis Cohort.

Authors:  Chelsea M Blankenship; Lisa L Hunter; M Patrick Feeney; Madison Cox; Lindsey Bittinger; Angela C Garinis; Li Lin; Gary McPhail; John P Clancy
Journal:  Am J Audiol       Date:  2021-01-19       Impact factor: 1.636

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.